Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest announcement is out from Shanghai Henlius Biotech, Inc. Class H ( (HK:2696) ).
Shanghai Henlius Biotech, Inc. announced that its New Drug Application for HANSIZHUANG, a serplulimab injection used in combination with chemotherapy for gastric cancer treatment, has been accepted by the National Medical Products Administration in China and granted priority review status. This development is based on successful phase 3 clinical trials demonstrating significant efficacy and safety improvements, potentially accelerating the drug’s market approval and enhancing the company’s position in the oncology sector.
The most recent analyst rating on (HK:2696) stock is a Hold with a HK$74.00 price target. To see the full list of analyst forecasts on Shanghai Henlius Biotech, Inc. Class H stock, see the HK:2696 Stock Forecast page.
More about Shanghai Henlius Biotech, Inc. Class H
Shanghai Henlius Biotech, Inc. is a biotechnology company based in China, focusing on the development of innovative monoclonal antibodies. The company is involved in producing treatments for various cancers, including lung, esophageal, and gastric cancers. Its products are marketed in several regions, including the European Union, United Kingdom, and various Asian countries, and it has received Orphan-drug Designation in multiple regions.
Average Trading Volume: 1,262,584
Technical Sentiment Signal: Buy
Current Market Cap: HK$35.73B
For an in-depth examination of 2696 stock, go to TipRanks’ Overview page.